Rachita Sarangi

Prof. Dr. Rachita Sarangi


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
SSSubrat Kumar Swain
Subrat Kumar Swain
SPSubhasmita Panda
Subhasmita Panda
BSBasanta Pravas Sahu
Basanta Pravas Sahu
RSRachita Sarangi
Rachita Sarangi
Enteroviruses are members of the Picornaviridae family consisting of human enterovirus groups A, B, C, and D as well as nonhuman enteroviruses. Human enterovirus type 71 (EV71) has emerged as a major cause of viral encephalitis, known as hand, foot, and mouth disease (HFMD), in children worldwide, especially in the Asia-Pacific region. EV71 and coxsackievirus A16 are the two viruses responsible for HFMD which are members of group A enteroviruses. The identified EV71 receptors provide useful information for understanding viral replication and tissue tropism. Host factors interact with the internal ribosome entry site (IRES) of EV71 to regulate viral translation. However, the specific molecular features of the respective viral genome that determine virulence remain unclear. Although a vaccine is currently approved, there is no effective therapy for treating EV71-infected patients. Therefore, understanding the host-pathogen interaction could provide knowledge in viral pathogenesis and further benefits to anti-viral therapy development. The aim of this study was to investigate the latest findings about the interaction of viral ligands with the host receptors as well as the activation of immunerelated signaling pathways for innate immunity and the involvement of different cytokines and chemokines during host-pathogen interaction. The study also examined the roles of viral proteins, mainly 2A and 3C protease, interferons production and their inhibitory effects.

1 January 2021 in Vaccine
Verified
Journal Article
Open access
MDManoja Das
Manoja Das
NANarendra Kumar Arora
Narendra Kumar Arora
RPRamesh Poluru
Ramesh Poluru
JTJacqueline Tate
Jacqueline Tate
BGBini Gupta
Bini Gupta
SGSaurabh Garge
Saurabh Garge
An association between rotavirus vaccination and intussusception has been documented in post-licensure studies in some countries. We evaluated the risk of intussusception associated with monovalent rotavirus vaccine (Rotavac) administered at 6, 10 and 14 weeks of age in India. Active prospective surveillance for intussusception was conducted at 22 hospitals across 16 states from April 2016 through September 2017. Data on demography, clinical features and vaccination were documented. Age-adjusted relative incidence for 1–7, 8–21, and 1–21 days after rotavirus vaccination in children aged 28–364 days at intussusception onset was estimated using the self-controlled case-series (SCCS) method. Only Brighton Collaboration level 1 cases were included. Out of 670 children aged 2–23 months with intussusception, 311 (46.4%) children were aged 28–364 days with confirmed vaccination status. Out of these, 52 intussusception cases with confirmed receipt of RVV were included in the SCCS analysis. No intussusception case was observed within 21 days of dose 1. Only one case occurred during 8–21 days after the dose 2. Post-dose 3, two cases in 1–7 days and 7 cases during 8–21 days period were observed. There was no increased risk of intussusception during 1–7 days after the doses 1 and 2 (zero cases observed) or dose 3 (relative incidence [RI], 1.71 [95% confidence interval {CI} 0.0–5.11]). Similarly, no increased risk during 8–21 days after the dose 1 (zero cases observed), dose 2 (RI, 0.71 [95% CI, 0.0–3.28]) or dose 3 (RI, 2.52 [95% CI, 0.78–5.61]). The results were similar for 1–21 day periods after the doses separately or pooled. The risk of intussusception during the first 21 days after any dose of rotavirus vaccine (Rotavac) was not higher among the Indian infants than the background risk, based on limited SCCS analysis of 52 children.

8 January 2022 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
SSSubrat Kumar Swain
Subrat Kumar Swain
AGAyushman Gadnayak
Ayushman Gadnayak
JMJatindra Nath Mohanty
Jatindra Nath Mohanty
RSRachita Sarangi
Rachita Sarangi
JDJayashankar Das
Jayashankar Das

1 October 2020 in Vaccine
Verified
Journal Article
Open access
MDManoja Das
Manoja Das
NANarendra Kumar Arora
Narendra Kumar Arora
BGBini Gupta
Bini Gupta
ASApoorva Sharan
Apoorva Sharan
KKK. Kameswari
K. Kameswari
ARArindam Ray
Arindam Ray
Intussusception has been linked with rotavirus vaccine (RVV) as a rare adverse reaction. In view of limited background data on intussusception in India and in preparation for RVV introduction, a surveillance network was established to document the epidemiology of intussusception cases in Indian children. Intussusception in children 2-23 months were documented at 19 nationally representative sentinel hospitals through a retrospective surveillance for 69 months (July 2010 to March 2016). For each case clinical, hospital course, treatment and outcome data were collected. Among the 1588 intussusception cases, 54.5% were from South India and 66.3% were boys. The median age was 8 months (IQR 6, 12) with 34.6% aged 2-6 months. Seasonal variation with higher cases were documented during March-June period. The most common symptoms and signs were vomiting (63.4%), bloody stool (49.1%), abdominal pain (46.9%) and excessive crying (42.8%). The classical triad (vomiting, abdominal pain, and blood in stools) was observed in 25.6% cases. 96.4% cases were diagnosed by ultrasound with ileocolic location as the commonest (85.3%). Management was done by reduction (50.8%) and surgery (41.1%) and only 1% of the patients' died. 91.1% cases met Brighton criteria level 1 and 3.3% Level 2. Between 2010 and 2015, the case load and case ratio increased across all regions. Intussusception cases have occurred in children across all parts of the country, with low case fatality in the settings studied. The progressive rise cases could indicate an increasing awareness and availability of diagnostic facilities.

1 September 2020 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
TGThe INCLEN Intussusception Surveillance Network Study Group
The INCLEN Intussusception Surveillance Network Study Group
MDManoja Das
Manoja Das
NANarendra Kumar Arora
Narendra Kumar Arora
BGBini Gupta
Bini Gupta
ASApoorva Sharan
Apoorva Sharan
CMChristine G. Maure
Christine G. Maure
Background: India introduced rotavirus vaccines (RVV, monovalent, Rotavac™ and pentavalent, Rotasiil™) in April 2016 with 6, 10 and 14 weeks schedule and expanded countrywide in phases. We describe the epidemiology of intussusception among children aged 2–23 months in India. Methods: The prospective surveillance at 19 nationally representative sentinel hospitals from four regions recruited children with intussusception from April 2016 to September 2017. Data on sociodemography, immunization, clinical, treatment and outcome were collected. Along with descriptive analysis, key parameters between four regions were compared using Chi-Square/Fisher’s exact/Mann–Whitney U/Kruskal-Wallis tests. The pre- and post-RVV periods were compared to estimate the risk ratios. Results: Six hundred twenty-one children with intussusception from South (n = 262), East (n = 190), North (n = 136) and West (n = 33) regions were recruited. Majority (n = 465, 74.8%) were infants (40.0% aged 4–7 months) with median age 8 months (IQR 5, 13 months), predominantly males (n = 408, 65.7%) and half (n = 311, 50.0%) occurred during March–June months. A shorter interval between weaning and intussusception was observed for ragi based food (median 1 month, IQR 0–4.2 months) compared to rice (median 4 months, IQR 1–9 months) and wheat (median 3 months, IQR 1–7 months) based food (p < 0.01). Abdominal pain or excessive crying (82.8%), vomiting (72.6%), and bloody stool (58.1%) were the leading symptoms. Classical triad (abdominal pain, vomiting and bloody stool) was observed in 34.8% cases (24.4 to 45.8% across regions). 95.3% of the cases were diagnosed by ultrasound. 49.3% (10.5 to 82.4% across regions) cases were managed by reduction, 39.5% (11.5 to 71.1% across regions) cases underwent surgery and 11.1% spontaneously resolved. Eleven (1.8%) cases died. 89.1% cases met Brighton criteria level 1 and 7.6% met Level 2. RVV was received by 12 cases within 1–21 days prior to intussusception. No increase in case load (RR = 0.44; 95% CI 0.22–1.18) or case ratio (RR = 0.5; 95% CI 0.3–1.2) was observed after RVV introduction in select sites. Conclusions: Intussusception cases were observed across all sites, although there were variations in cases, presentation and mode of management. The high case load age coincided with age of the RVV third dose. The association with ragi based weaning food in intussusception needs further evaluation.

1 July 2016 in Pediatria Polska
Verified
Journal Article
Closed access
RSRachita Sarangi
Rachita Sarangi
SPSarita Pradhan
Sarita Pradhan
NDNagen Ch Debata
Nagen Ch Debata
SMSitaram Mahapatra
Sitaram Mahapatra
Odisha in the eastern region of India has been witnessing an increased incidence of pediatric scrub typhus. The present study was undertaken to study the clinical profile, laboratory parameters, complications and efficacy to therapy in scrub typhus. Prospective observational study. Total 71 children up to 14 years of age who had fever for more than 5 days without an identifiable cause were included in the study. All suspected cases were tested with Weil-Felix test (OX-K ≥ 1:80 positive) and IgM antibody (ELISA) against Orientia tsutsugamushi. All IgM positive cases were further studied for response to Azithromycin therapy. Twenty six children were diagnosed with scrub typhus between July 2015 and December 2015. The age of patients ranged from eleven months to twelve years. Majority of patients (69.2%) were from rural areas. The common symptoms were fever, headache, hepatomegaly, lymphadenopathy and serosal effusions. Eschar was seen only in 30.7% of cases. Leucocytosis was seen in 76.9% of cases and 61.5% of cases had anicteric hepatitis. Commonest complications seen were hepatitis (61.5%) and pneumonia (38.4%). All cases responded well to Azithromycin therapy. Our result showed that scrub typhus should be suspected in all cases of fever without an identifiable cause irrespective of age. Serosal effusions and anicteric hepatitis must raise the possibility of scrub typhus among clinicians.